Ground Swell Capital’s CorMedix CRMD Stock Holding History

Ground Swell Capital’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-72	Closed	-$1K	–	2445
2014 Q2	$1K	Buy	+72	New	+$614	﹤0.01%	1695

Other funds holding CRMD

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

GLRA

Gerald L. Ray & Associates Dallas, Texas $802M AUM 21.01% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Ground Swell Capital's CRMD Position: Q3 2014 in Review

Ground Swell Capital sold out of CorMedix (CRMD) in Q3 2014, closing a stake of 72 shares — an estimated $1K sold.

Ground Swell Capital first reported a position in CRMD in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 11 funds tracked by Wall St. Rank hold CRMD as of Q3 2014.

Ground Swell Capital reported no remaining CorMedix position as of Q3 2014 after selling out during the quarter.
Ground Swell Capital sold 72 CorMedix shares in Q3 2014, an estimated $1K.
Ground Swell Capital first reported a position in CorMedix in Q2 2014 and held it in 1 quarter.
Ground Swell Capital's CorMedix position peaked at $1K in Q2 2014.
11 funds tracked by Wall St. Rank held CorMedix as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.